Cargando…
Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a basel...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271003/ https://www.ncbi.nlm.nih.gov/pubmed/35818415 http://dx.doi.org/10.1155/2022/3684181 |
_version_ | 1784744585016115200 |
---|---|
author | Thanvi, Vikas |
author_facet | Thanvi, Vikas |
author_sort | Thanvi, Vikas |
collection | PubMed |
description | Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD. |
format | Online Article Text |
id | pubmed-9271003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92710032022-07-10 Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms Thanvi, Vikas Case Rep Psychiatry Case Report Evidence suggests that inhibition of protein kinase C (PKC) signalling may have a contributing role in the treatment of bipolar affective disorder (BPAD). Endoxifen, an active metabolite of tamoxifen, is a potent direct PKC inhibitor. This report presents a severe case of a BPAD patient with a baseline Young Mania Rating Scale (YMRS) score of 49, associated family history and addiction to psychostimulants, with no improvement by the first and second-generation antipsychotics. Treatment with endoxifen 8 mg once a day showed improvement in manic symptoms with a YMRS score of 4 and a reduction in the use of psychostimulants as well as other antipsychotic concomitant medications. No adverse effects were noted up to 8-month follow-up. Long-term treatment with endoxifen is safe and effective in severe BPAD. Hindawi 2022-07-02 /pmc/articles/PMC9271003/ /pubmed/35818415 http://dx.doi.org/10.1155/2022/3684181 Text en Copyright © 2022 Vikas Thanvi. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Thanvi, Vikas Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title_full | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title_fullStr | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title_full_unstemmed | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title_short | Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms |
title_sort | real-world long-term experience on endoxifen in bipolar disorder with psychotic symptoms |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271003/ https://www.ncbi.nlm.nih.gov/pubmed/35818415 http://dx.doi.org/10.1155/2022/3684181 |
work_keys_str_mv | AT thanvivikas realworldlongtermexperienceonendoxifeninbipolardisorderwithpsychoticsymptoms |